-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The biopharmaceutical industry is an important industry related to the national economy and people's livelihood, and is closely related to the people's healthy living needs and the protection of national health and safety
.
2021 is the first year of the 14th Five-Year Plan, and all regions are planning the pace of development for the next five years, sounding the new clarion call for high-quality industrial development
.
Jiangsu Province regards the biomedical industry as an important foundation for economic resilience.
In recent years, with the support of a series of policies, the scale of the biomedical industry in this region has continued to expand.
In 2020, the output value of the biomedical industry in Jiangsu Province will account for about 1/6 of the national total
.
It is reported that through R&D empowerment, the province's biomedical companies have achieved continuous innovation in multiple fields such as innovative drugs and medical devices
.
Among them, in the field of innovative drugs, in the first half of 2021, Jiangsu Province applied for 427 new drug registrations, a year-on-year increase of 38.
2%, and approved 145 drugs for marketing, an increase of 2.
4 times compared with the same period last year.
The cumulative number of innovative drugs and improved new drugs 12, accounting for over 40% of domestically produced innovative drugs
.
In addition, in the field of medical devices, the industry is also continuing to develop with high quality with the help of innovation.
In 2020, Jiangsu will newly list 1,957 second- and third-class medical devices, accounting for more than 10% of the country’s total, of which 180 are third-class medical devices, accounting for Nearly 20% of the national total
.
On November 15th, Nanjing Novazan Biotechnology Co.
, Ltd.
listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, further demonstrating the R&D and innovation capabilities of enterprises in the province
.
In order to encourage enterprises to continue to innovate, Jiangsu Province has also sent out real policy "red envelopes
.
" On November 1, Jiangsu Province’s "Several Policies and Measures on Promoting the High-Quality Development of the Province’s Biomedical Industry" was formally implemented, which clearly stated that in the next three years, it will provide financial support for the innovation of biomedical companies in the province
.
For example, in the development of new drugs, different levels of support will be given to innovative drugs and improved new drugs according to different clinical trial stages and marketing production stages; clinical research will be included in the performance evaluation of medical institutions, and for hospitals that have obtained the qualifications of clinical trial institutions, by 2024 In 2010, the proportion of clinical research beds in the total number of hospital beds increased to about 10%; support the introduction of the world’s best talents and teams, and project funding of up to 100 million yuan
.
Up to now, Jiangsu Province has gathered 4,453 biopharmaceutical companies including Hengrui Pharmaceuticals, Osaikon, Yangtze River Pharmaceuticals, Jiangsu Hausen, Tasly, etc.
, including 599 pharmaceutical manufacturers and 3536 medical device manufacturers
.
In 2020, the pharmaceutical industry above designated size in Jiangsu Province will achieve operating income of 435.
684 billion yuan and profit of 67.
012 billion yuan
.
According to the ambition for the development of the biomedical industry in the next five years in Jiangsu Province, the average annual growth rate of the operating income of the pharmaceutical industry above designated size in the province during the 14th Five-Year Plan was maintained at about 10%, and the proportion of innovative products in the industrial structure continued to increase.
By 2025, Jiangsu's pharmaceutical industry will achieve world-class industrial quality and efficiency, innovation capabilities, openness and coordination, domestically leading corporate strength, industrial ecology, and high-quality industrial development at the forefront of the country.
It will develop into an advanced manufacturing cluster with global influence and the world.
Highland of well-known innovative drugs
.
The "14th Five-Year" Pharmaceutical Industry Development Plan of Jiangsu Province also mentioned innovation capabilities again in terms of specific goals, clarifying that during the "14th Five-Year" period, R&D investment continued to increase, and corporate innovation capabilities were significantly improved, which promoted the establishment of national-level innovation carriers in Jiangsu layout building a number of R & D in the trial, clinical trial safety evaluation services platform
.
.
2021 is the first year of the 14th Five-Year Plan, and all regions are planning the pace of development for the next five years, sounding the new clarion call for high-quality industrial development
.
Jiangsu Province regards the biomedical industry as an important foundation for economic resilience.
In recent years, with the support of a series of policies, the scale of the biomedical industry in this region has continued to expand.
In 2020, the output value of the biomedical industry in Jiangsu Province will account for about 1/6 of the national total
.
It is reported that through R&D empowerment, the province's biomedical companies have achieved continuous innovation in multiple fields such as innovative drugs and medical devices
.
Among them, in the field of innovative drugs, in the first half of 2021, Jiangsu Province applied for 427 new drug registrations, a year-on-year increase of 38.
2%, and approved 145 drugs for marketing, an increase of 2.
4 times compared with the same period last year.
The cumulative number of innovative drugs and improved new drugs 12, accounting for over 40% of domestically produced innovative drugs
.
In addition, in the field of medical devices, the industry is also continuing to develop with high quality with the help of innovation.
In 2020, Jiangsu will newly list 1,957 second- and third-class medical devices, accounting for more than 10% of the country’s total, of which 180 are third-class medical devices, accounting for Nearly 20% of the national total
.
On November 15th, Nanjing Novazan Biotechnology Co.
, Ltd.
listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, further demonstrating the R&D and innovation capabilities of enterprises in the province
.
In order to encourage enterprises to continue to innovate, Jiangsu Province has also sent out real policy "red envelopes
.
" On November 1, Jiangsu Province’s "Several Policies and Measures on Promoting the High-Quality Development of the Province’s Biomedical Industry" was formally implemented, which clearly stated that in the next three years, it will provide financial support for the innovation of biomedical companies in the province
.
For example, in the development of new drugs, different levels of support will be given to innovative drugs and improved new drugs according to different clinical trial stages and marketing production stages; clinical research will be included in the performance evaluation of medical institutions, and for hospitals that have obtained the qualifications of clinical trial institutions, by 2024 In 2010, the proportion of clinical research beds in the total number of hospital beds increased to about 10%; support the introduction of the world’s best talents and teams, and project funding of up to 100 million yuan
.
Up to now, Jiangsu Province has gathered 4,453 biopharmaceutical companies including Hengrui Pharmaceuticals, Osaikon, Yangtze River Pharmaceuticals, Jiangsu Hausen, Tasly, etc.
, including 599 pharmaceutical manufacturers and 3536 medical device manufacturers
.
In 2020, the pharmaceutical industry above designated size in Jiangsu Province will achieve operating income of 435.
684 billion yuan and profit of 67.
012 billion yuan
.
According to the ambition for the development of the biomedical industry in the next five years in Jiangsu Province, the average annual growth rate of the operating income of the pharmaceutical industry above designated size in the province during the 14th Five-Year Plan was maintained at about 10%, and the proportion of innovative products in the industrial structure continued to increase.
By 2025, Jiangsu's pharmaceutical industry will achieve world-class industrial quality and efficiency, innovation capabilities, openness and coordination, domestically leading corporate strength, industrial ecology, and high-quality industrial development at the forefront of the country.
It will develop into an advanced manufacturing cluster with global influence and the world.
Highland of well-known innovative drugs
.
The "14th Five-Year" Pharmaceutical Industry Development Plan of Jiangsu Province also mentioned innovation capabilities again in terms of specific goals, clarifying that during the "14th Five-Year" period, R&D investment continued to increase, and corporate innovation capabilities were significantly improved, which promoted the establishment of national-level innovation carriers in Jiangsu layout building a number of R & D in the trial, clinical trial safety evaluation services platform
.
